首页> 美国卫生研究院文献>BMC Cancer >Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial
【2h】

Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial

机译:一期研究评估碳离子放射疗法对局部晚期胰腺癌患者的治疗:PHOENIX-01试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTreatment options for patients with locally advanced pancreatic cancer include surgery, chemotherapy as well as radiotherapy. In many cases, surgical resection is not possible, and therefore treatment alternatives have to be performed. Chemoradiation has been established as a convincing treatment alternative for locally advanced pancreatic cancer. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 1.16 and 2.46 depending on the pancreatic cancer cell line as well as the endpoint analyzed. Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for patients with pancreatic cancer.
机译:背景技术对于局部晚期胰腺癌患者的治疗选择包括手术,化学疗法以及放射疗法。在许多情况下,不可能进行手术切除,因此必须执行其他治疗方案。化学放疗已被确立为局部晚期胰腺癌的一种令人信服的治疗选择。碳离子具有物理和生物学特性。由于其颠倒的剂量分布和布拉格峰内的高局部剂量沉积,可以对正常组织进行精确的剂量施用和备用。此外,与光子相比,碳离子具有更高的相对生物有效性(RBE),可以根据胰腺癌细胞系和分析的终点计算得出其相对生物有效性(RBE)在1.16和2.46之间。日本对碳离子放射疗法进行评估的数据显示,对于胰腺癌患者,其结果令人鼓舞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号